University of Texas: New Targeted Therapy Blocks Metabolism in Brain Cancer Cells With Genetic Vulnerability
November 24, 2020
November 24, 2020
HOUSTON, Texas, Nov. 24 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Nov. 23:
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of . . .
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of . . .